Role of Polycystic Ovary Syndrome in Increasing Susceptibility to COVID-19: A Biochemical and Psychological Approach

The effect of comorbidities on coronavirus 2019 susceptibility and prognosis is of recent research interest. Polycystic ovary syndrome must be considered one of the comorbidities owing to the influence of hyperandrogenic conditions on increasing expression of viral receptor such as transmembrane serine protease and angiotensin-converting enzyme-2. Obesity and undesirable adipocyte accumulation increase hospitalization rate. Insulin resistance induces abnormal cytokine production and impairs T cell functions. The renin-angiotensin system hyperactivity and neuropilin-1 upregulation increase viral entry. Impaired gastric microbiota and Vitamin D deficiency lead to inflammation. Hypertension, cardiovascular ailment, hair loss, anxiety, and depression are consistent in coronavirus 2019 patients. This review addresses the comprehensive role of biochemical and psychological aspects of polycystic ovary disease on immune functions against severe acute respiratory syndrome coronavirus-2 infection. The study provides knowledge on the up-to-date mechanisms related to coronavirus infectivity on polycystic ovary syndrome women and shall help healthcare professionals to consider inclusive treatment options for such patients. However, there are numerous gaps in the therapeutical and molecular mechanisms involved in polycystic ovary syndrome and its heterogenous role as a comorbidity in coronavirus infection.